Yun Zhong
Stock Analyst at Wedbush
(3.45)
# 961
Out of 5,099 analysts
43
Total ratings
57.89%
Success rate
3.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Initiates: Outperform | $32 | $22.17 | +44.34% | 12 | Dec 9, 2025 | |
| ASND Ascendis Pharma | Reiterates: Outperform | $220 | $196.63 | +11.89% | 3 | Nov 18, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $18 → $20 | $21.31 | -6.15% | 2 | Nov 11, 2025 | |
| KROS Keros Therapeutics | Maintains: Neutral | $15 → $16 | $21.53 | -25.69% | 3 | Nov 6, 2025 | |
| IRD Opus Genetics | Initiates: Outperform | $8 | $2.39 | +234.73% | 1 | Oct 29, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Outperform | $70 → $86 | $88.56 | -2.89% | 3 | Oct 28, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Outperform | $80 → $18 | $14.55 | +23.71% | 2 | Sep 30, 2025 | |
| PASG Passage Bio | Maintains: Outperform | $3 → $40 | $10.40 | +284.62% | 3 | Aug 13, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $28 | $6.28 | +345.86% | 1 | Aug 11, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Outperform | $9 → $8 | $4.29 | +86.48% | 2 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $4.60 | +73.91% | 1 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 | $3.36 | +852.38% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $9.85 | +21.83% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $28 | $4.41 | +534.92% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.31 | - | 2 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $9.81 | +63.10% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $20.78 | +121.37% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.18 | +358.72% | 1 | May 5, 2021 |
Sarepta Therapeutics
Dec 9, 2025
Initiates: Outperform
Price Target: $32
Current: $22.17
Upside: +44.34%
Ascendis Pharma
Nov 18, 2025
Reiterates: Outperform
Price Target: $220
Current: $196.63
Upside: +11.89%
Wave Life Sciences
Nov 11, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $21.31
Upside: -6.15%
Keros Therapeutics
Nov 6, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $21.53
Upside: -25.69%
Opus Genetics
Oct 29, 2025
Initiates: Outperform
Price Target: $8
Current: $2.39
Upside: +234.73%
Protagonist Therapeutics
Oct 28, 2025
Maintains: Outperform
Price Target: $70 → $86
Current: $88.56
Upside: -2.89%
MoonLake Immunotherapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $80 → $18
Current: $14.55
Upside: +23.71%
Passage Bio
Aug 13, 2025
Maintains: Outperform
Price Target: $3 → $40
Current: $10.40
Upside: +284.62%
Sagimet Biosciences
Aug 11, 2025
Initiates: Outperform
Price Target: $28
Current: $6.28
Upside: +345.86%
Voyager Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $4.29
Upside: +86.48%
May 27, 2025
Initiates: Outperform
Price Target: $8
Current: $4.60
Upside: +73.91%
May 16, 2025
Reiterates: Outperform
Price Target: $32
Current: $3.36
Upside: +852.38%
Nov 5, 2024
Initiates: Outperform
Price Target: $12
Current: $9.85
Upside: +21.83%
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $4.41
Upside: +534.92%
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $5.31
Upside: -
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $9.81
Upside: +63.10%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $20.78
Upside: +121.37%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $2.18
Upside: +358.72%